0 of 82 Questions completed
Questions:
You have already completed this quiz. You cannot start it again.
Quiz is loading…
You must sign in or sign up to take this quiz.
You must first complete the following:
Quiz complete. Results are being recorded.
0 of 82 Questions answered correctly
Your Time:
Time has elapsed.
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
A 23-year-old Caucasian woman presents with a six-month history of progressive weight gain and amenorrhea. Her physical examination is significant for moderate hirsutism, facial plethora, and multiple violaceous striae involving the abdomen. She is noted to have significant hyperpigmentation of her palmar creases. A 1mg overnight dexamethasone suppression test was significant for a post suppression cortisol level of 3 mcg/dL. Pituitary MRI showed a 1.2 cm adenoma on the right side of the pituitary gland. Inferior petrosal sinus sampling (IPSS) confirmed the diagnosis of an ACTH-dependent cause of hypercortisolemia originating from the pituitary gland. The patient underwent an unsuccessful transsphenoidal surgery and subsequently required medical therapy (ketoconazole) to control her hypercortisolemia.
She reports to your clinic with new-onset headaches and muscle weakness. Her workup reveals severe hypertension and hypokalemia. A further increase in the dose of ketoconazole results in worsening hypertension and hypokalemia. What is the likely cause of her presentation?
A 23-year-old Caucasian woman presents with a six-month history of progressive weight gain and amenorrhea. Her physical examination is significant for moderate hirsutism, facial plethora, and multiple violaceous striae involving the abdomen. She is noted to have significant hyperpigmentation of her palmar creases. A 1mg overnight dexamethasone suppression test was significant for a post suppression cortisol level of 3 mcg/dL. What is the most likely diagnosis?
A 23-year-old female with celiac disease presents with a 10-pound unintentional weight loss over four weeks, palpitations, and diarrhea. She reports anterior neck pain. She is noted to have anterior neck pain on the physical exam. An I-123 radioactive iodine scan was low. ESR was elevated at 120mm/hr. Her TSH was suppressed at <0.01 (reference range 0.5—4.1 mIU/L) with a free T4 of 3.7 (reference range 0.7-1.5 ng/dL) and free T3 of 12.4 (reference range 2.0-4.1 ng/dL. Which of the following regarding the patient’s prognosis is accurate?
A 23-year-old obese woman with polycystic ovary syndrome is referred to the reproductive endocrinology clinic. She is being scheduled for an assisted reproductive procedure. The patient requests metformin be added to her treatment regimen. Which of these statements is true regarding the role of metformin in anovulatory infertility.
A 24-year-old woman presents with new-onset galactorrhea and a 3-month history of amenorrhea. Her urine pregnancy screen is negative. Serum prolactin level of 98 ng/mL (4-30 ng/mL), normal serum IGF-1, normal ACTH and 8 AM cortisol, normal free T4. A dedicated pituitary MRI showed a 4 mm adenoma. Which of the following management timelines is incorrect?
A 26-year-old female with Graves disease, well-controlled on thionamide therapy. Which of the following is not a good predictor of long-term remission after a drug holiday?
A 32-year-old female with a 6-month history of amenorrhea is noted to have a diagnostic Cushingoid body habitus during her physical examination. Her urine pregnancy test is negative. A 1 mg overnight dexamethasone suppression test is significant for a post-suppression cortisol level of 4 mcg/dL. 24-hour urinary free cortisol and late-night salivary cortisol levels were 2 and 3 times above the upper limit of normal, respectively. Plasma ACTH is elevated at baseline. A dedicated pituitary MRI showed a 3mm sellar lesion. What is the best next step in the evaluation of this patient?
A 32-year-old man with postoperative hypoparathyroidism reports for his annual check-up. His serum calcium is 6.2 (8.5-10.5 mg/dL. He is symptomatic of hypocalcemia (acral paraesthesias and muscle cramps). He endorses compliance with calcitriol 2mcg daily and calcium 6000mg daily. His 24hour urine calcium is elevated at 623mg/24hrs (normal reference <325mg per 24hours). 25-OH vitamin D is 43 (30-80). You elect to start him on recombinant human parathyroid hormone rhPTH(1-84). How is this form of exogenous parathyroid hormone different from PTH(1-34), the form utilized in the treatment of osteoporosis.
A 34-year-old woman with oligomenorrhea is diagnosed with polycystic ovary syndrome. She is prescribed spironolactone and oral contraceptives due to severe acne and hirsutism. Which of these effects can be attributed to the mechanism of action of spironolactone?
A 23-year-old Caucasian woman presents with a six-month history of progressive weight gain and amenorrhea. Her physical examination is significant for moderate hirsutism, facial plethora, and multiple violaceous striae involving the abdomen. She is noted to have significant hyperpigmentation of her palmar creases. A 1mg overnight dexamethasone suppression test was significant for a post suppression cortisol level of 7 mcg/dL. Which of the following interpretations of the dexamethasone suppression test in the evaluation of endogenous hypercortisolemia is true?
A 43-year-old man presents with an 8-month history of fatigue, lack of libido, and increasing central belly fat. He has a remote history of brain radiotherapy 15 years earlier. Physical examination was significant for truncated eyebrows, dry, doughy skin, and delayed relaxation phase of his deep tendon reflexes at the ankles. Serum testosterone (measured at 9 am, fasting) was 50 ng/dL (250-800 ng/dL), low LH, low FSH, TSH of 1.2 (reference range 0.5—4.1 mIU/L), normal prolactin and low IGF-1 (age and gender-matched). You performed a random cortrosyn stimulation test after his early morning cortisol returned borderline low. His post-stimulation cortisol level was, however, appropriate after 30 minutes. What is the next best step in the evaluation of this patient?
A 45-year-old female is diagnosed with a 3.5cm left adrenal incidentaloma. The lesion has a low attenuation value on non-contrast CT consistent with a benign adenoma. She has no significant past medical history. Her blood pressure is 116/62mmHg. Her serum potassium is 4.0. What is the next best step in the management of this patient?
A 45-year-old is diagnosed with an invasive macroprolactinoma and is started on medical treatment. He is subsequently diagnosed with compulsive gambling and sexual inappropriateness. What is the most likely cause?
A 45-year-old man presents with a 5-year history of poor libido. He is noted to have significant acral enlargement, prognathism, and bilateral carpal tunnel syndrome. IGF-1 is noted to be elevated up to 2 times the upper limit of normal. You perform an oral glucose tolerance test with 75grams of anhydrous glucose. His nadir serum growth hormone is inappropriately elevated at 2.3 ng/dL after two hours. The patient is diagnosed with a 12mm growth hormone-secreting macroadenoma and undergoes transsphenoidal surgery. He, unfortunately, has progressive persistent disease post-surgery and is started on appropriate medical therapy. The patient, however, develops significant elevation in serum transaminases within a few weeks of treatment. Which of the following medications is associated with this side effect?
A 46-year-old Caucasian woman presents with a six-month history of progressive weight gain. Her physical examination is significant for moderate hirsutism, facial plethora, and multiple violaceous striae involving the abdomen. She is also noted to have significant hyperpigmentation of her palmar creases. A 1mg overnight dexamethasone suppression test was significant for a post suppression cortisol level of 8 mcg/dL. Pituitary MRI showed a 1.6 cm adenoma on the right side of the pituitary gland. Inferior petrosal sinus sampling (IPSS) confirmed the diagnosis of an ACTH-dependent cause of hypercortisolemia originating from the pituitary gland. The patient underwent an unsuccessful transsphenoidal surgery and subsequently required medical therapy (mifepristone) to control her symptoms.
She reports to your clinic with new-onset fatigue, nausea, and colicky abdominal pain. She is hypotensive, and further workup reveals a random serum cortisol level of 43 (5-15 mcg/dL). What is the likely cause of her presentation?
A 46-year-old man presented with an 8-year history of poor libido and a 1-year history of migraine headaches with visual symptoms. He also reported increased fatigue and profuse sweating. A “photograph biopsy” was significant for a marked change in his facial features over the past ten years. Physical examination was significant for increased interdental distance. He had significant acanthosis nigricans and multiple acrochordons involving flexural areas. Visual field testing suggested bitemporal hemianopsia. A contrast-enhanced T1 weighted MRI showed a pituitary adenoma measuring 2x3x2.5cm with suprasellar extension and chiasmal optic impingement.
Serum IGF-1 1256 ng/mL (Upper limit of normal for age and gender being <315 ng/Ml). A mid-morning random growth hormone level of 45 ng/mL (normal <4 ng/mL. A 75gram oral glucose tolerance test was significant for GH levels of 35, 28.9, 23.4, 22.1, and 20.7 ng/mL at baseline, 30,60,90, and 120 minutes, respectively. His other pituitary hormonal axes were intact during preoperative workup. He subsequently underwent transsphenoidal surgery. The pathology report reported a cytokeratin staining pattern in round perinuclear structures (fibrous bodies) consistent with a sparsely granulated somatotroph adenoma.
A 75-gram oral glucose tolerance test was repeated a week after surgery. Post suppression growth hormone levels were 2.1, 1.1, 1, 0.9, 0.8 and 0.9 at baseline, 30, 60, 90 and 120 minutes respectively. The detection limit of the growth hormone assay for this laboratory is 0.01 ng/mL.
Which of the following statements is true
A 47-year-old woman with a history of celiac disease and post-traumatic stress disorder presents with a six-month history of persistent hyperthyroidism of unclear etiology. She has a small and non-tender thyroid gland on physical examination. Which of the following investigations will be most helpful in distinguishing subacute lymphocytic (painless) thyroiditis from factitious consumption of thyroid hormone by the patient?
A 52-year-old postmenopausal woman presents with a 12-month history of distressing vasomotor symptoms. She has a history of total abdominal hysterectomy. Your patient has completed a recent google search regarding the risks and benefits of menopausal hormone therapy. Which of the following statements made by the patient is accurate?
A 52-year-old woman presents with a 2-year history of progressive weight gain. Her physical examination for a BMI of 38 kg/m2 and a supraclavicular fat pad. She has a low baseline DHEA sulfate and ACTH. A 1mg overnight dexamethasone suppression test was significant for a post suppression cortisol level of 5.2 mcg/dL. What is the most likely diagnosis?
A 54-year-old woman with hypertension, atrial fibrillation, coronary artery disease (status post two coronary stent placements), diabetes mellitus, and a recent distal radial fracture presents to your office on account of elevated serum TSH in the setting of elevated free T4 and free T3. A pituitary MRI was normal with an elevated serum alpha subunit of pituitary glycoprotein. What is the best next step in the evaluation of this patient?
A 55-year-old female is diagnosed with a 2cm right adrenal incidentaloma. The lesion has a low attenuation value on non-contrast CT consistent with a benign adenoma. She has no significant past medical history. Screening tests of hormonal hypersecretion returned reassuringly normal. Which of the following scenarios is not an indication for referral to surgery?
A 69-year-old man presents with a 5-year history of poor libido. He is noted to have significant acral enlargement, prognathism, and bilateral carpal tunnel syndrome. IGF-1 is noted to be elevated up to 2 times the upper limit of normal. You perform an oral glucose tolerance test with 75grams of anhydrous glucose. His nadir serum growth hormone is inappropriately elevated at 2.3 ng/dL after two hours. The patient is diagnosed with a 12mm growth hormone-secreting macroadenoma and undergoes transsphenoidal surgery. He, unfortunately, has progressive persistent disease post-surgery and is started on appropriate medical therapy. The patient, however, develops severe hyperglycemia within a few weeks of treatment. Which of the following medications is the most likely cause?
A patient presents with recent onset fatigue and general malaise. She is noted to have a normal TSH, low free T3 and a low free T4. Her reverse T3 level is high. What is her most likely diagnosis?
A patient with newly diagnosed type 2 diabetes should participate in a comprehensive diabetes self-management education program that includes all of the following EXCEPT:
Consider which option is not directly related to managing diabetes.
Which of the following is NOT a goal of medical nutrition therapy (MNT) in patients with type 2 diabetes?
Think about which goal might not be sustainable or healthy in the long term.
Which of the following medication classes promotes weight loss and helps prevent weight gain due to other glucose-lowering pharmacotherapies in patients with type 2 diabetes?
Consider which medication class has a notable impact on weight management.
What is the recommended amount of moderate-intensity aerobic activity for adults with diabetes per week?
Think about a reasonable amount of exercise spread over at least three days per week.
Which of the following is a reasonable glycemic management target for most patients with type 2 diabetes?
Consider the balance between reducing microvascular complications and the risk of hypoglycemia.
Which intervention has been shown to result in diabetes remission for some patients with type 2 diabetes?
Think about an intervention that can lead to significant weight loss and improvement in insulin resistance.
In addition to glycemic management, which factor should be a top priority for patients with type 2 diabetes?
Consider the importance of reducing the risk of complications related to type 2 diabetes.
What type of exercise is recommended for adults with type 2 diabetes to decrease sedentary time?
Consider the duration and intensity of the recommended exercise for adults with type 2 diabetes.
A 52-year-old man with a BMI of 28 kg/m2 is diagnosed with type 2 diabetes. His A1C is 8.2%. What is the recommended initial pharmacologic therapy for this patient?
Consider the benefits of metformin, such as glycemic efficacy, promotion of modest weight loss, low incidence of hypoglycemia, general tolerability, and favorable cost.
In the Look AHEAD trial, which of the following was a primary outcome?
Think about the cardiovascular outcomes related to intensive lifestyle interventions in the Look AHEAD trial.
Which of the following is a contraindication for metformin use in patients with type 2 diabetes?
Consider which condition may affect the safety of metformin use in patients with type 2 diabetes.
In patients with type 2 diabetes, what is the main goal of intensive lifestyle modification interventions?
Consider the main focus of lifestyle interventions in managing type 2 diabetes.
Which of the following noncardiac benefits was observed in the Look AHEAD trial's intensive lifestyle intervention group?
Recall
In patients with type 2 diabetes, what is a reasonable target for glycated hemoglobin (A1C) levels?
The target A1C level should balance the reduction in microvascular complications with the risks of hypoglycemia and other adverse effects of therapy.
Which medication is generally suggested as the initial therapy for most patients with type 2 diabetes?
This medication is often initiated at the time of diabetes diagnosis and is titrated to its maximally effective dose over one to two months.
When is metformin contraindicated in patients with type 2 diabetes?
Metformin should not be administered when the patient has severely reduced kidney function or conditions that predispose to lactic acidosis.
For patients with type 2 diabetes and cardiorenal comorbidities who cannot take metformin, which class of medications is suggested?
These medications have demonstrated cardiorenal benefits and are chosen based on shared decision-making, considering beneficial and adverse effects, comorbidities, and patient preferences.
A 45-year-old patient is newly diagnosed with type 2 diabetes and has an A1C of 7.8%. What initial pharmacologic therapy do you recommend?
Metformin is generally the first-line treatment for type 2 diabetes due to its efficacy, promotion of modest weight loss, low incidence of hypoglycemia, general tolerability, and favorable cost.
A patient with type 2 diabetes has an A1C of 7.3% and is highly motivated to make lifestyle changes. How long should they be given to try lifestyle modification before initiating pharmacologic therapy?
Patients who are highly motivated and have an A1C near target should be given a trial period of lifestyle modification before starting pharmacologic therapy.
In patients with type 2 diabetes and established cardiovascular or kidney disease, which class of medications has demonstrated cardiovascular and kidney benefits?
The correct class of medications has shown favorable cardiovascular and kidney outcomes in patients with type 2 diabetes and established cardiovascular or kidney disease.
Which medication is not recommended for initiation in patients with type 2 diabetes and an eGFR <30 to 45 mL/min/1.73 m2 due to diminishing effects with lower eGFR?
The correct class of medications has diminishing effects in patients with type 2 diabetes and lower eGFR.
A patient with type 2 diabetes has not achieved their individualized glycemic treatment goal within three months with metformin plus lifestyle intervention. What is the most appropriate next step according to the ADA and EASD consensus guideline?
Consider what the guidelines recommend when the glycemic treatment goal is not achieved within three months.
Which of the following is a conventional glucose goal for patients with type 2 diabetes aiming for an A1C goal <7 percent?
Recall the conventional glucose goals for patients aiming for an A1C goal <7 percent.
Which of the following factors can contribute to worsening glycemia in patients with type 2 diabetes?
Consider the factors that can negatively impact glycemic control.
A 55-year-old patient with type 2 diabetes and an A1C >9 percent presents with persistent symptoms of hyperglycemia. Which of the following medications is suggested as a second-line treatment in this case?
Consider the medications with the best glycemic efficacy for patients with an A1C >9 percent or persistent symptoms of hyperglycemia.
Which of the following insulin types has been commonly used at bedtime to supplement oral hypoglycemic drug therapy?
Consider the type of insulin that has historically been used to supplement oral hypoglycemic drug therapy.
In a patient with type 2 diabetes and established ASCVD, which medication is typically preferred as an add-on therapy to metformin?
Consider the GLP-1 receptor agonists with demonstrated cardiovascular benefits.
For patients with type 2 diabetes and heart failure or diabetic kidney disease, which medication is the recommended add-on therapy to metformin?
Consider the medication class that has demonstrated benefits for cardiovascular and kidney outcomes, especially for heart failure hospitalization and risk of kidney disease progression.
A 52-year-old patient with type 2 diabetes and an eGFR of 40 mL/min/1.73 m2 is not reaching glycemic goals with metformin alone. Which of the following agents would be an appropriate alternative or addition to their treatment plan?
Consider agents with glycemic benefits independent of kidney function.
In which patient group should the use of SGLT2 inhibitors be avoided?
Consider the risk factors that could be exacerbated by SGLT2 inhibitors.
Which medication should be used cautiously in patients with type 2 diabetes and advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m2)?
Consider the potential risks and benefits of the medication for patients with advanced chronic kidney disease.
Based on the GRADE trial results, which medication had the lowest proportion of individuals with weight gain of ≥10 percent?
Consider the medication's impact on weight management.
Which medication class is associated with a low risk of hypoglycemia and may be preferable for patients who need to avoid hypoglycemia?
Consider the medication class's likelihood of causing hypoglycemia.
A 55-year-old patient with type 2 diabetes has an A1C of 8.5% despite being on metformin and a sulfonylurea. What is the most appropriate next step in management?
Consider the most effective options for improving glycemic control when initial combination treatment does not achieve target A1C.
Which medication class may decrease insulin dose requirements when added to a patient's regimen, but requires close follow-up and insulin dose adjustment to reduce the risk of hypoglycemia?
This medication class has been shown to have cardiovascular benefits and works by inhibiting glucose reabsorption in the kidneys.
In patients with type 2 diabetes inadequately managed with two agents, what is one potential advantage of switching to insulin rather than adding a third oral or injectable agent?
Consider the financial implications of treatment options when multiple agents do not achieve adequate glycemic control.
When initiating insulin therapy in a patient with type 2 diabetes, which medication is usually discontinued due to reduced efficacy and adverse effects?
This medication class works by stimulating insulin secretion from the pancreas and is often used in combination with metformin.
A patient with type 2 diabetes and persistent hyperglycemia on metformin monotherapy has an A1C of 8.5% and established ASCVD. What would be the most appropriate second agent to add to their treatment plan?
Consider the patient's established ASCVD when choosing the second agent.
Which of the following medication classes should not be combined in the treatment of type 2 diabetes?
Think about the mechanism of action of the medications.
A patient with type 2 diabetes and A1C >9 percent without catabolic symptoms or existing cardiac disease is considering a second agent. Which medication may be favored when weight loss is important?
Consider the impact on weight for each medication.
For patients with type 2 diabetes and obesity class II or III, what treatment option is suggested in addition to lifestyle measures and optimal medical therapy?
Consider the BMI criteria for the suggested treatment option.
A 35-year-old woman presents with a 9-month history of irregular menstrual cycles and occasional milky discharge from her breasts. She also reports intermittent headaches and slightly blurred vision. Her past medical history includes hypothyroidism, well-controlled on levothyroxine 75 mcg daily. On examination, blood pressure is 118/76 mm Hg, heart rate is 78/min, and there are no focal neurological deficits. Laboratory studies show:Serum prolactin: 98 ng/mL (normal: 5–20 ng/mL)TSH: 1.3 mIU/L (reference range: 0.5–4.5 mIU/L)Free T4: 1.1 ng/dL (reference range: 0.8–1.8 ng/dL)Which of the following is the best next step in management?
Think about how to confirm the suspected anatomical cause of her high prolactin and visual complaints.References:Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288.Capozzi A, Scambia G, Pontecorvi A, Lello S. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol. 2015;31(7):506–510.
A 29-year-old man presents with decreased libido, erectile dysfunction, and chronic fatigue for the past eight months. He has no significant past medical history. On physical exam, he has mild bilateral gynecomastia. Vital signs are stable. Laboratory results show:Serum prolactin: 65 ng/mL (normal: <20 ng/mL)Total testosterone: 200 ng/dL (reference range: 280–800 ng/dL)TSH: 2.1 mIU/L (reference range: 0.5–4.5 mIU/L)Which of the following is the most appropriate next step in management?
Hyperprolactinemia often suppresses gonadotropin secretion leading to low testosterone and warrants pituitary imaging.References:Grigg J, Worsley R, Thew C, et al. Antipsychotic-induced hyperprolactinemia: synthesis of worldwide guidelines and integrated recommendations for assessment, management, and future research. Psychopharmacology (Berl). 2017;234(22):3279–3290.Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288.
A 42-year-old woman with a known microprolactinoma (6 mm) returns for follow-up. She has been on bromocriptine 2.5 mg twice daily for four months. She complains of persistent nausea and occasional dizziness. Despite treatment, her serum prolactin is 80 ng/mL (previously 90 ng/mL). She continues to have amenorrhea and intermittent galactorrhea. MRI of the sella turcica shows stable tumor size with no suprasellar extension.Which of the following is the best next step in management?
Another dopamine agonist can help when bromocriptine causes side effects or fails to normalize prolactin.References:Capozzi A, Scambia G, Pontecorvi A, Lello S. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol. 2015;31(7):506–510.Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288.
A 39-year-old woman with a macroprolactinoma (1.3 cm) returns for evaluation. She has been on cabergoline 0.5 mg twice weekly for six months. Her headaches and breast discharge have improved, but her menses remain infrequent. Recent labs show a serum prolactin level of 30 ng/mL (previously 120 ng/mL). Follow-up MRI shows the tumor is now 1.1 cm with no suprasellar extension. She reports no visual field disturbances.Which of the following is the most appropriate next step in management?
Optimizing her current regimen by adjusting the dopamine agonist dose is the logical next step given her partial response.References:Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288.Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol. 2011;7(5):267–278.
A 27-year-old woman who is 3 months postpartum presents with persistent galactorrhea and absent menses since childbirth. She breastfed for only 2 weeks and then switched to formula feeding. Her past medical history is unremarkable. Laboratory results show:Serum prolactin: 85 ng/mL (normal: 5–20 ng/mL)TSH: 1.6 mIU/L (reference range: 0.5–4.5 mIU/L)Serum beta-hCG: negativePhysical examination reveals no visual field deficits. She denies headache or other neurologic symptoms.Which of the following is the best next step in management?
Remember that unexplained hyperprolactinemia and amenorrhea require pituitary imaging to confirm or exclude a prolactinoma.References:Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288.Capozzi A, Scambia G, Pontecorvi A, Lello S. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol. 2015;31(7):506–510.
A 52-year-old man presents with abrupt onset of severe headache and blurry peripheral vision for the past 24 hours. He has had long-standing elevated prolactin levels (500–800 ng/mL range) but declined any treatment. Current exam reveals bitemporal hemianopsia and a blood pressure of 140/88 mm Hg. An urgent MRI of the brain shows a 2.5-cm pituitary lesion with evidence of hemorrhage.Which of the following is the best next step in management?
Remember that pituitary apoplexy is a surgical emergency.References:Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry. 2001;71(4):542–545.Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288.
A 34-year-old woman presents with a 5-month history of amenorrhea and fatigue. She also mentions occasional nipple discharge. Review of systems reveals that she started a new antipsychotic medication (risperidone) 6 months ago. Laboratory studies show:Serum prolactin: 50 ng/mL (normal: 5–20 ng/mL)Serum beta-hCG: negativeTSH: 1.8 mIU/L (0.5–4.5 mIU/L)She has no headaches or vision changes. Physical exam is otherwise unremarkable.Which of the following is the most appropriate initial approach to manage her hyperprolactinemia?
Remember that some medications can raise prolactin levels; adjusting these drugs is often the first intervention.References:Grigg J, Worsley R, Thew C, et al. Antipsychotic-induced hyperprolactinemia: synthesis of worldwide guidelines and integrated recommendations for assessment, management, and future research. Psychopharmacology (Berl). 2017;234(22):3279–3290.Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288.Top of Form
A 39-year-old man presents with progressive changes in facial appearance and an increase in his shoe and ring sizes over the past 2 years. He also reports fatigue, joint pain, and occasional headaches. On examination, he has coarse facial features, mild macroglossia, and enlarged hands (difficult ring removal). Blood pressure is 150/88 mm Hg. Laboratory testing reveals:Fasting plasma glucose: 116 mg/dL (reference: 70–99 mg/dL)IGF-1: 780 ng/mL (reference: 100–300 ng/mL, age-adjusted)Which of the following is the most appropriate next step in establishing the diagnosis?
Remember that a random GH level can fluctuate and is not diagnostic; OGTT-based GH suppression is the gold standard.References:Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951.Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-3148.
A 45-year-old woman with confirmed acromegaly due to a 1.2 cm GH-secreting pituitary adenoma undergoes transsphenoidal surgery. Three months postoperatively, her serum IGF-1 remains elevated at 450 ng/mL (reference: 100–300 ng/mL, age-adjusted). A repeat pituitary MRI shows a small residual intrasellar lesion. She complains of persistent sweating, acral enlargement, and fatigue.Which of the following is the best next step in her management?
Think about standard algorithms for acromegaly: transsphenoidal resection first, then medical therapy (somatostatin analogs, GH receptor antagonists, etc.) if IGF-1 remains uncontrolled.References:Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552-561.Giustina A, Barkan A, Beckers A, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. 2020;105(4):e937-e946.
A 28-year-old woman presents with a 1-year history of progressive weight gain, irregular menses, easy bruising, and fatigue. Examination shows centripetal obesity, purplish abdominal striae, mild proximal muscle weakness, and a round “moon” face. Her blood pressure is 150/90 mm Hg. Laboratory tests reveal:Serum cortisol after 1 mg overnight dexamethasone suppression: 12 µg/dL (reference: <1.8 µg/dL)Serum ACTH: 60 pg/mL (reference: 10–60 pg/mL)Which of the following is the best next step in distinguishing between pituitary (Cushing’s disease) and ectopic sources of ACTH?
Remember that pituitary ACTH-producing adenomas often retain partial sensitivity to glucocorticoid feedback, whereas ectopic sources generally do not.References:Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540.Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611-629.
A 35-year-old man is diagnosed with persistent Cushing’s disease (CD) despite prior transsphenoidal resection of a pituitary microadenoma. He has persistent hypertension, hyperglycemia, and elevated 24-hour urinary free cortisol. A repeat MRI shows no visible remnant tumor. He prefers to avoid radiation if possible. Which of the following is the most appropriate next step?
Consider that adrenal-blocking agents often precede more invasive interventions in cases of persistent hypercortisolism without visible tumor.References:Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831.Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing’s disease. Endocr Rev. 2015;36(4):385-486.Bottom of Form
A 42-year-old man is being evaluated for persistent acromegaly despite prior transsphenoidal resection of a GH-secreting pituitary macroadenoma. His serum IGF-1 remains elevated (3.0 × upper limit of normal) and repeat MRI shows a small suprasellar extension. He complains of persistent arthralgias and headaches.Which of the following is the most appropriate next step in management?
Think about medical therapy escalation: if standard somatostatin analogs or dopamine agonists are insufficient, pasireotide and/or pegvisomant may be next, particularly with significant residual disease.References:Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–561.Coopmans EC, Muhammad A, van der Lely AJ, et al. How to position pasireotide LAR treatment in acromegaly. J Clin Endocrinol Metab. 2019;104(6):1978–1988.
A 35-year-old woman presents with mild hypercortisolism that has fluctuated over several months. She reports episodes of facial rounding, weight gain, and menstrual irregularities that spontaneously improve for weeks at a time. Recent labs show:24-hour urinary free cortisol (UFC): intermittently elevatedLate-night salivary cortisol: elevated on two tests, normal on two other testsSerum ACTH: high-normalWhich of the following is the most likely explanation for these findings?
Remember that cyclical Cushing’s involves periods of normal cortisol interspersed with overt hypercortisolism.References:Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–1540.Aranda G, Enseñat J, Mora M, et al. Long-term remission and recurrence rate in a cohort of Cushing’s disease: the need for long-term follow-up. Pituitary. 2015;18(1):142–149.
A 50-year-old man with recurrent Cushing’s disease underwent transsphenoidal resection twice, and pituitary MRI still shows a small remnant lesion. Over the past year, his hypercortisolism has been controlled with ketoconazole 600 mg/day, but now he reports severe fatigue, nausea, and elevated liver enzymes. Laboratory tests show:AST: 150 U/L (reference: <40 U/L)ALT: 162 U/L (reference: <40 U/L)Bilirubin: 3 mg/dL (reference: 0.3–1.2 mg/dL)The patient has persistent hyperglycemia and hypertension.He wishes to stop ketoconazole due to side effects. Which of the following is the most appropriate next step?
Remember that mifepristone blocks cortisol action at the receptor level and can help manage hyperglycemia in Cushing’s disease.References:Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–2831.Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing’s disease. Endocr Rev. 2015;36(4):385–486.
A 48-year-old man presents with chronic headaches and progressive loss of peripheral vision over the past 6 months. MRI reveals a 2.5 cm sellar mass extending into the suprasellar region without evidence of hormone hypersecretion on preliminary labs. Which of the following findings would most strongly suggest that this is a non-functioning pituitary adenoma?
Think of “non-functioning” as having no hormone hypersecretion but often causing hypopituitarism due to mass effect.References:Chanson P, Raverot G, Castinetti F, et al. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol. 2015;76(3):239–247.Ntali G, Wass JA. Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary. 2018;21(2):111–118.
A 55-year-old woman is diagnosed with a 1.8 cm non-functioning pituitary macroadenoma. She has mild headaches but no visual deficits and normal pituitary function. Which of the following is the best initial management approach?
Non-functioning macroadenomas that are asymptomatic and not impinging on vital structures can be followed conservatively unless there’s significant growth or pituitary dysfunction.References:Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017;317(5):516–524.Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4):894–904.
A 62-year-old man underwent transsphenoidal surgery for a large non-functioning pituitary macroadenoma that was causing bitemporal hemianopsia. Postoperatively, imaging shows a small residual tumor, and pathology indicates a gonadotroph subtype with a Ki-67 labeling index of 4%. Which of the following is the best statement regarding his prognosis or treatment plan?
A Ki-67 over 3% often correlates with more aggressive growth patterns; consider radiotherapy or close imaging follow-up.References:Ceccato F, Regazzo D, Barbot M, et al. Early recognition of aggressive pituitary adenomas: a single-centre experience. Acta Neurochir. 2018;160(1):49–55.Esposito D, Olsson DS, Ragnarsson O, et al. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary. 2019;22(4):422–434.
A 60-year-old woman presents 10 years after transsphenoidal resection of a non-functioning pituitary macroadenoma. She has been well until recently, when she developed new headaches and mild visual changes. MRI reveals regrowth of the residual tumor with suprasellar extension approaching the optic chiasm. She has stable pituitary hormone function on testing. Which of the following is the most appropriate next step?
When a non-functioning macroadenoma regrows, causing mass effect on vision, repeat surgery is typically the preferred intervention.References:Castinetti F, Dufour H, Gaillard S, et al. Non-functioning pituitary adenoma: when and how to operate? Ann Endocrinol. 2015;76(3):220–227.Raverot G, Assié G, Cotton F, et al. Biological and radiological exploration and management of non-functioning pituitary adenoma. Ann Endocrinol. 2015;76(3):201–209.